

- **Name:** Jeffrey Crawford MD, FASCO
 - **Current Position & Affiliation:** George Barth Galler Professor for Research in Cancer, Department of Medicine, Duke University Medical Center
 - **Country:** USA
-

• Educational Background:

Professor Jeffrey Crawford MD is a graduate of Ohio Wesleyan University and Ohio State University School of Medicine. He completed his training in internal medicine and hematology oncology at Duke University.

• Professional Experience:

Over his career at Duke, Dr Crawford has served as clinical director of the thoracic oncology program, chief of the division of medical oncology, and associate director for clinical research for the Duke Cancer Institute. Dr. Crawford has had a long-term commitment to the National Cancer Institute clinical trials and has served in a number of leadership positions within Cancer and Leukemia Group B and the Alliance and is currently the site principal investigator for Alliance studies in the Duke Cancer Institute.

Dr Crawford's research has been in clinical trials in lung cancer with a focus on supportive care. He has published more than 250 articles. His expertise includes the role of hematopoietic growth factors for the management of chemotherapy induced myelosuppression, as well as the study of novel agents for cancer cachexia.

• Professional Organizations:

- Fellow of American Society of Clinical Oncology (FASCO) - **2023**
- Duke Department of Medicine Career Achievement Award - **2023**
- Richard L. Schilsky CALGB Achievement Award - **2023**
- Board of Directors, Society of Cachexia and Wasting Disorders - **2023**
- Associate Editor, Journal of Cachexia, Sarcopenia and Muscle Wasting (JCS M) – **2019**
- Chair, Finance Committee Alliance Foundation - **2019**
- Principal Investigator for Duke Cancer Institute, National Clinical Trial Network LAPS Grant -**2014**
- Principal Investigator, Alliance for Clinical Trials in Oncology - **2011**
- Member, Respiratory Committee, Alliance (Vice-chair 2011-2013) - **2011**

• Selected Scientific Publications:

Groarke JD, **Crawford J**, Collins SM, Lubaczewski S, Roeland EJ, Naito T, Hendifar AE, Fallon M, Takayama K, Asmis T, Dunne RF, Karahanoglu I, Northcott CA,

Harrington MA, Rossulek M, Qiu R, Saxena AR. Pongegromab for the Treatment of Cancer Cachexia. *N Engl J Med*. 2024 Dec 19;391(24):2291-2303. PMID: 39282907

Dunne RF, **Crawford J**, Smoyer KE, McRae TD, Rossulek MI, Revkin JH, Tarasenko LC, Bonomi PD. The mortality burden of cachexia or weight loss in patients with colorectal or pancreatic cancer: A systematic literature review. *J Cachexia Sarcopenia Muscle*. 2024 Oct;15(5):1628-1640. PMCID: PMC11446707

Bonomi P, **Crawford J**, Dunne R, Roeland E, Smoyer K, Siddiqui M, McRae T, Rossulek M, Revkin K, Tarasenko, L. Mortality burden of cachexia in patients with non-small-cell lung cancer: A systematic literature review and meta-analysis. *J Cachexia Sarcopenia Muscle*. 2024 Aug;15(4):1226-1239. PMCID: PMC11294038

Crawford J, Calle RA, Collins SM, Weng Y, Labaczewski SL, Buckeridge C, Wang EQ, Harrington MA, Tarachandani A, Rossulek MI, Revkin JH. A Phase 1B First-In-Patient study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of Pongegromab in participants with cancer and cachexia. *Clin Cancer Res*. 2024 Feb 1;30(3):489-497.

Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, Winder T, Zukov R, Garbaos G, Gao S, Kuroda H, Ostoros G, Tran TV, You J, Lee KY, Antonuzzo L, Papai-Szekely Z, Akamatsu H, Biswas B, Spira A, **Crawford J**, Le HT, Aperghis M, Doherty GJ, Mann H, Fouad TM, Reck M; AEGEAN Investigators. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. *N Engl J Med*. 2023 Nov 2;389(18):1672-1684

Crawford J, Oswalt C. The impact of new and emerging agents on outcomes for febrile neutropenia: addressing clinical gaps. *Curr Opin Oncol* 2023 Jul 1;35(4):241-247

Crawford J, Blackwell S, Barbour S. Adapting to Change: A Thoracic Oncology Team's Perspective. *JCO Oncology Practice* 19, no. 7 (July 01, 2023) 392-394

Oswalt C, Liu Y, Pang H, Le-Radmacher J, Wang X, **Crawford J**. Associations between body mass index, weight loss and overall survival in patients with advanced lung cancer. *Journal of Cachexia, Sarcopenia and Muscle* 2022;13: 2650–2660. PMID: 36268548

Crawford J. What are the criteria for response to cachexia treatment? *Ann Palliat Med*. 2019 Jan;8(1):43-49.

Crawford J. Cancer cachexia: Are we ready to take a step forward? *Cancer* Volume 124, Issue 3, February 01, 2018, Pages: 456–458. PMID: 29205293

Kinsey E, Ajazi E, Wang X, Johnston MAM, **Crawford J**. Predictors of physical and functional loss in advanced stage lung cancer patients receiving platinum chemotherapy. J Thorac Oncol. 2018 Jul 4. PMID:29981438

Le-Rademacher JG, **Crawford J**, Evans WJ, Jatoi A. Overcoming obstacles in the design of cancer anorexia/weight loss trials. Crit Rev Oncol Hematol. 2017 Sep; 117:30-37. PMCID: PMC5561667

Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991 Jul 18;325(3):164-70.